In a bid to double revenues in the next three years, Aurobindo Pharma is focusing on new markets and also on cost-reduction across all areas. In the US and European markets, new product launches and supply chain initiatives would drive growth and the company is banking on strong demand for its basket of products in Europe. The demand for generics is on the rise with governments everywhere are focusing on low-cost healthcare.
Recently, the company received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Orally Disintegrating Tablets (ODT) 5mg and 10mg. The Abbreviated New Drug Application (ANDA) 203062 is ready for launch.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
